Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Accumulated Expenses (2024 - 2026)

Maze Therapeutics' Accumulated Expenses history spans 3 years, with the latest figure at $5.4 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 53.07% to $5.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.4 million, a 53.07% decrease, with the full-year FY2025 number at $16.0 million, up 13.23% from a year prior.
  • Accumulated Expenses hit $5.4 million in Q1 2026 for Maze Therapeutics, down from $16.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for MAZE hit a ceiling of $16.0 million in Q4 2025 and a floor of $5.4 million in Q1 2026.
  • Historically, Accumulated Expenses has averaged $11.2 million across 3 years, with a median of $12.8 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: grew 13.23% in 2025 and later plummeted 53.07% in 2026.
  • Tracing MAZE's Accumulated Expenses over 3 years: stood at $14.1 million in 2024, then increased by 13.23% to $16.0 million in 2025, then tumbled by 66.09% to $5.4 million in 2026.
  • Business Quant data shows Accumulated Expenses for MAZE at $5.4 million in Q1 2026, $16.0 million in Q4 2025, and $14.4 million in Q3 2025.